Ideas
Patent protection defends Novo's obesity franchise.
Novo Nordisk's obesity drugs are protected by patents, and regulators should not allow compounded copycats without trials and FDA approval; this legal/regulatory moat defends its Wegovy/Ozempic franchise against copycats such as Hims & Hers.
Lilly dominates obesity drugs with better efficacy.
Eli Lilly has dominated the obesity/GLP-1 market because Zepbound is a dual-action drug that beat Wegovy in a head-to-head trial with higher efficacy and better weight loss; Lilly also had a strong diabetes device and mass-market distribution, while Novo has been more specialist-focused.
Strong balance sheet supports massive AI borrowing.
Alphabet is tapping global debt markets, including a rare 100-year sterling bond, as part of the AI borrowing boom; its AA credit rating and best-in-class balance sheet make it a premier AI credit, but investors should watch whether future hyperscaler supply pressures debt pricing.
Insurance ownership differentiates Apollo's private credit lending.
Apollo's ownership of insurance providers gives it a different origination model and more capacity than peers to lend into investment-grade private credit; it originated a record $97 billion in Q4 and has kept software exposure near zero.
Market leadership broadening beyond tech.
Market leadership is broadening beyond tech, with small caps (S&P 600), mid-caps, and international markets making fresh highs; the transfer from tech to the broader market supports the underlying trend.
Gold downgraded after extended run.
Truist downgraded gold near recent highs because it was about 40% above its trading average and may need time to consolidate, even though structural drivers remain.
Software unlikely to regain market leadership.
Software may not regain leadership; the rubber band keeps stretching and the AI disruption question is hard to disprove, even though earnings trends are relatively solid.
Tech will eventually resume leadership.
Do not give up on tech; valuations have reset from roughly 32x to 23x while earnings trends remain strongest in the market, so tech can regain leadership after the broadening phase.
Copycat GLP-1 strategy faces regulatory crackdown.
Hims & Hers built a business selling compounded GLP-1 copycats and bet that regulators and Novo would not act; after Novo's lawsuit and FDA pressure, it scrapped its Wegovy copycat and shares collapsed, exposing significant regulatory and legal risk.
New CEO could improve Kroger operations.
Kroger's appointment of former Walmart U.S. executive Greg Foran as CEO is viewed positively because he is a proven grocery operator who improved Walmart's stores and grocery offering; this could drive a Kroger operational turnaround, though he must manage a portfolio of many chains.
Enterprise software selloff creates selective opportunities.
The software selloff is creating babies thrown out with bathwater; enterprise software integrated into complex tech stacks is hard to replace, which can buy time to adapt to AI and potentially benefit.
AI productivity benefits small caps, international.
AI benefits should eventually accrue to end users as productivity works through the economy, which can support small caps and companies in other countries, extending market broadening.
Arctos deal targets $100B sports, secondaries.
KKR's acquisition of Arctos gives it leading positions in sports, secondaries, and GP solutions, two of the hottest private-market growth areas, and management believes the combination can build a $100 billion-plus business.
Misunderstood quarter masks improving Edgewell fundamentals.
Edgewell beat fiscal Q1 organic sales, profit and cash flow, and the headline guidance cut reflects the timing of the Fem Care sale; the sale was at a premium, reduces leverage and gives flexibility, while the remaining shave/grooming/sun/skincare portfolio can drive growth and margin expansion.
Activist sees Swatch undervalued, needing board change.
Swatch's market share has collapsed from 40% to under 20% and its long-tenured board lacks independent perspective; Wood is a long-term committed investor pushing for board changes, luxury focus, and innovation to revive the brand, and the watch industry is improving.
This Bloomberg Markets video, published February 09, 2026,
features Sam Fazeli, Caroline Hyde, Silas Brown, Keith Lerner, Madison, Emily Cohn, Kelly Covley, Rob, Rod Little, Steven Wood
discussing NVO, LLY, Alphabet bonds, APO, IJR, Mid-cap equities, ACWX, GLD, IGV, XLK, HIMS, KR, IWM, KKR, EPC, UHR.SW.
15 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Sam Fazeli,
Caroline Hyde,
Silas Brown,
Keith Lerner,
Madison,
Emily Cohn,
Kelly Covley,
Rob,
Rod Little,
Steven Wood
· Tickers:
NVO,
LLY,
Alphabet bonds,
APO,
IJR,
Mid-cap equities,
ACWX,
GLD,
IGV,
XLK,
HIMS,
KR,
IWM,
KKR,
EPC,
UHR.SW
